Loading clinical trials...
Loading clinical trials...
A Phase II Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Daily Dose of Lapatinib in Advanced Breast Cancer Patients With HER-2 Non-amplified Primary Tumours and HER-2 Positive Circulating Tumour Cells or EGFR Positive Circulating Tumor Cells
Conditions
Interventions
LAPATINIB
Locations
10
Italy
GSK Investigational Site
Rimini, Emilia-Romagna, Italy
GSK Investigational Site
Udine, Friuli Venezia Giulia, Italy
GSK Investigational Site
Bergamo, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Rozzano (MI), Lombardy, Italy
GSK Investigational Site
Livorno, Tuscany, Italy
Start Date
June 1, 2008
Primary Completion Date
July 1, 2011
Completion Date
July 1, 2011
Last Updated
March 28, 2012
NCT04915755
NCT00490139
NCT00272987
NCT05814224
NCT00251433
NCT01905592
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions